Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

Facade of AstraZeneca's office in Shanghai, China

Mergers & acquisitions

AstraZeneca Buys FibroGen’s China Unit for $160M as Probes Continue

A year ago, AstraZeneca walked away from the bulk of its roxadustat partnership with FibroGen—though the pharma at the time decided to retain its relationship with the biotech’s China operations.

February 20, 2025

2 min read

Tristan Manalac

Contemporary art collage showing a hand giving a thumbs down surrounded by red arrows pointing down, concept of negative feedback and bad review

Regulatory

FDA Kicks Down Harmony’s Bid to Push Wakix Into Idiopathic Hypersomnia

Despite the regulatory setback, analysts appear optimistic, noting that Harmony’s long-term prospects remain bright given the development of its high-dose formulation of its sleep-regulating drug Wakix.

February 20, 2025

2 min read

Tristan Manalac

Government

FTC Doubles Down on Tighter Merger Rules Despite Trump’s Pro-Industry Posture

Despite expectations of dealmaking leniency, new FTC chairman Andrew Ferguson told staff that he will retain the current 2023 FTC and DOJ guidelines on mergers, upholding stricter anti-trust scrutiny on deals.

February 20, 2025

2 min read

Tristan Manalac

Business

Philadelphia’s Life Sciences Scene Making Its Mark

The Philadelphia market has gained recognition not only for its cell and gene therapy sector but also its real estate scene and talent pool. Vittoria Biotherapeutics, Interius BioTherapeutics and Chamber of Commerce for Greater Philadelphia executives share why the area is a life sciences hot spot.

February 20, 2025

7 min read

Angela Gabriel

Job Trends

6 Companies Hiring in Pennsylvania

Looking for a biopharma job in Pennsylvania? Check out the BioSpace list of six companies hiring life sciences professionals like you.

February 20, 2025

1 min read

Angela Gabriel

Depression

Supernus Falls Back on CNS Portfolio as Depression Drug Fails Mid-Stage Study

After SPN-820’s failure, Supernus is relying on its non-stimulant ADHD drug Qelbree and the recently approved Parkinson’s therapy Onapgo to sustain the company.

February 20, 2025

2 min read

Tristan Manalac

Hands reach out to each other. Handshake. Halftone retro hands. Paper cutout elements. Trendy vintage newspaper parts. Hands tied with thread. Shaking hands. Make a deal. Successful agreement

Cancer

Merck and Epitopea Join Forces to Identify Unknown Tumor Antigens

The agreement, in which Merck will pay the biotech an undisclosed initial sum to license drugs targeting a solid tumor, could net Epitopea up to $300 million down the line.

February 19, 2025

1 min read

Dan Samorodnitsky

Business consultant. Hands help a businessman is falling from a graph vector

Bankruptcy

Biopharma Bankruptcies Still At Peak, With Little Relief in Sight

2023 marked the most bankruptcies in biopharma in more than a decade, with 14 companies filing for Chapter 11 protection. The number remained high in 2024.

February 19, 2025

5 min read

Annalee Armstrong